Duvic, Madeleine

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood

Cutaneous lymphoproliferative disorders researchDermatology and Skin Diseases

Cited by 1,141

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results

Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology

Cutaneous lymphoproliferative disorders researchNonmelanoma Skin Cancer Studies

Cited by 706

Central hypothyroidism associated with retinoid X receptor-selective ligands

Sherman, S. I., Gopal, J., Haugen, B. R., Chiu, A. C., Whaley, K., Nowlakha, P., & Duvic, M. (1999) · New England Journal of Medicine

Thyroid Disorders and TreatmentsCutaneous lymphoproliferative disorders research

Cited by 315

Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., Dusza, S. W., & Kuzel, T. M. (2014) · Blood

Cutaneous lymphoproliferative disorders researchLymphoma Diagnosis and Treatment

Cited by 93

BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling

Vin, H., Ojeda, S. S., Ching, G., Leung, M. L., Chitsazzadeh, V., Dwyer, D. W., Adelmann, C. H., Restrepo, M., Richards, K. N., Stewart, L. R., et al. (2013) · eLife

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 84